Brief: Cadrenal Therapeutics Receives US FDA Orphan Drug Designation For Tecarfarin
09/04/2024 14:46
April 9 (Reuters) - Cadrenal Therapeutics Inc CVKD.O :
* CADRENAL THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
TECARFARIN FOR PREVENTION OF THROMBOEMBOLISM AND THROMBOSIS IN
PATIENTS WITH LVADS, RVADS, BIVENTRICULAR ASSIST DEVICES, AND
TOTAL ARTIFICIAL HEARTS
* CADRENAL THERAPEUTICS INC: FDA DESIGNATION PROVIDES
POTENTIALLY
SEVEN YEARS OF MARKET EXCLUSIVITY AFTER APPROVAL FOR TECARFARIN
Source text for Eikon: ID:nPn7H1QMda
Further company coverage: CVKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology